Obnyx 80 Tablets Obnyx 80 contains Enzalutamide, an androgen receptor inhibitor that targets multiple steps in the androgen receptor signaling pathway. It competitively blocks androgen binding, prevents nuclear translocation of the receptor, and inhibits DNA binding of the activated receptor. It is indicated for treating adult men with metastatic and non-metastatic castration-resistant prostate cancer (CRPC) and metastatic castration-sensitive prostate cancer (mCSPC).